|Talimogene laherparepvec improves durable response rate in patients with advanced melanoma|
RH Andtbacka, HL Kaufman, F Collichio, T Amatruda, N Senzer, ...
J clin Oncol 33 (25), 2780-2788, 2015
|Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma|
I Puzanov, MM Milhem, D Minor, O Hamid, A Li, L Chen, M Chastain, ...
Journal of Clinical Oncology 34 (22), 2619, 2016
|Weighted gene coexpression network analysis: state of the art|
W Zhao, P Langfelder, T Fuller, J Dong, A Li, S Hovarth
Journal of biopharmaceutical statistics 20 (2), 281-300, 2010
|Network neighborhood analysis with the multi-node topological overlap measure|
A Li, S Horvath
Bioinformatics 23 (2), 222-231, 2007
|Aromatase expression predicts survival in women with early-stage non–small cell lung cancer|
V Mah, DB Seligson, A Li, DC Márquez, II Wistuba, Y Elshimali, ...
Cancer research 67 (21), 10484-10490, 2007
|Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected …|
HK Igor Puzanov, Mohammed M. Milhem, Robert Hans Ingemar Andtbacka, David R ...
Journal of Clinical Oncology 32 (5s), suppl; abstr 9029, 2014
|Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants|
OQP Yin, N Gallagher, A Li, W Zhou, R Harrell, H Schran
The Journal of Clinical Pharmacology 50 (2), 188-194, 2010
|Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score|
JS Lam, DB Seligson, H Yu, A Li, M Eeva, AJ Pantuck, G Zeng, S Horvath, ...
BJU international 98 (2), 445-451, 2006
|Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating …|
HL Kaufman, RHI Andtbacka, FA Collichio, T Amatruda, NN Senzer, ...
Journal of Clinical Oncology 32 (15_suppl), 9008a-9008a, 2014
|A group sequential Holm procedure with multiple primary endpoints|
Y Ye, A Li, L Liu, B Yao
Statistics in Medicine 32 (7), 1112-1124, 2013
|Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB …|
I Puzanov, MM Milhem, RHI Andtbacka, DR Minor, O Hamid, A Li, J Chou, ...
Journal of Clinical Oncology 33 (15_suppl), 9063-9063, 2015
|Network module detection: Affinity search technique with the multi-node topological overlap measure|
A Li, S Horvath
BMC research notes 2 (1), 1-14, 2009
|Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV …|
RHI Andtbacka, FA Collichio, T Amatruda, N Senzer, J Chesney, ...
Journal for ImmunoTherapy of Cancer 2 (3), 1-2, 2014
|Elevated MED28 expression predicts poor outcome in women with breast cancer|
NK Yoon, EL Maresh, Y Elshimali, A Li, S Horvath, DB Seligson, D Chia, ...
BMC cancer 10 (1), 1-9, 2010
|Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for …|
RHI Andtbacka, M Chastain, A Li, M Shilkrut, MI Ross
Journal of Clinical Oncology 33 (15_suppl), TPS9094-TPS9094, 2015
|Higher expression levels of 14-3-3σ in ductal carcinoma in situ of the breast predict poorer outcome 1|
NK Yoon, DB Seligson, D Chia, Y Elshimali, G Sulur, A Li, S Horvath, ...
Cancer Biomarkers 5 (4-5), 215-224, 2009
|Results of the extension trial of OPTiM, a multicenter, randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs GM-CSF for unresected stage IIIB-IV melanoma|
JJ Nemunaitis, RH Andtbacka, M Ross, T Amatruda, J Chesney, ...
Annals of Oncology 25, iv382, 2014
|Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in …|
I Puzanov, M Milhem, R Andtbacka, D Minor, O Hamid, A Li, ...
Journal for ImmunoTherapy of Cancer 1 (1), 1-2, 2013
|Efficacy and safety of ATA129, partially matched allogeneic third-party Epstein-Barr virus-targeted cytotoxic T lymphocytes in a multicenter study for post-transplant …|
S Prockop, A Li, RA Baiocchi, N Bunin, KM Mahadeo, ER Nemecek, ...
Blood 130 (Supplement 1), 4520-4520, 2017
V Mah, DB Seligson, A Li
DC, Wistuba, II, Elshimali, Y., Fishbein, MC, Chia, D., Pietras, RJ, and …, 2007